First study niraparib

Author: hwlo

August undefined, 2024

WebFeb 17, 2024 · Evidence-based recommendations on niraparib (Zejula) for maintenance treatment of advanced (FIGO stages 3 and 4) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer after response to first-line platinum-based chemotherapy in adults.. Is this guidance up to date? More evidence on niraparib is being collected, until … WebFeb 16, 2024 · Chi et al. Phase 3 MAGNITUDE study: First results of niraparib (NIRA) with abiraterone acetate and prednisone (AAP) as first-line therapy in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) with and without homologous recombination repair (HRR) gene alterations. ASCO GU 2024.

JASPER: Phase 2 trial of first‐line niraparib plus …

Web1 day ago · A study of IMP4297 as maintenance treatment following first-line chemotherapy in patients with advanced ovarian cancer (FLAMES). ClinicalTrials.gov. Updated February 12, 2024. Accessed April 12, 2024. WebApr 29, 2024 · On April 29, 2024, niraparib was approved for maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal … shape of you stormzy karaoke youtube

Real‐world outcomes of niraparib treatment in patients with …

WebSep 6, 2024 · The study had a single arm: All participants were prescribed niraparib 300 mg per day, which was given as oral capsules. In order to assess the effectiveness of … WebThe study was conducted in accordance with the eth-ical standards of the Declaration of Helsinki, and the ... ZEJULAR (Niraparib) for First-Line Maintenance Treat-mentofOvarianCancerinChina[Internet].GlobeNewswire News Room. 2024 [cited 2024 May 17]. Available from: WebNiraparib is also in development for use in other solid tumours, including breast and prostate cancer. This article summarizes the milestones in the development of niraparib … shape of you ten hours

JASPER: Phase 2 trial of first-line niraparib plus ... - PubMed

WebJan 1, 2024 · This study f … The JASPER clinical trial studied a new combination treatment for advanced or metastatic non-small cell lung cancer (NSCLC). ... ≥50% (cohort 1) or 1%-49% (cohort 2) received first-line niraparib (200 mg once daily) plus pembrolizumab (200 mg every 3 weeks). The primary end point was investigator-assessed objective response ... WebJan 1, 2024 · The JASPER clinical trial studied a new combination treatment for advanced or metastatic non-small cell lung cancer (NSCLC). Pembrolizumab, a drug approved for … shape of you samWebFeb 18, 2024 · “The MAGNITUDE study results support niraparib plus abiraterone as a new first-line treatment option for patients with mCRPC and alterations in genes associated with HRR,” lead study author Kim N. Chi, MD, senior research scientist, Vancouver Prostate Centre, chief medical officer and vice president, BC Cancer, medical oncologist, BC … shape of you sllash

"WebFeb 16, 2024 · Phase 3 MAGNITUDE study: First results of niraparib (NIRA) with abiraterone acetate and prednisone (AAP) as first-line therapy in patients (pts) with … " - First study niraparib

First study niraparib

First-Line Niraparib Maintenance Improves PFS in Advanced …

WebNov 30, 2024 · A study of niraparib combined with MGD013 in patients with advanced or metastatic solid tumor who failed prior treatment. clinicaltrials.gov. Updated April 1, 2024. Accessed November 30, 2024 ... WebApr 11, 2024 · The phase III PRIMA study randomized 733 patients with stage III/IV ovarian cancer who responded to first-line platinum-based chemotherapy in a 2:1 ratio to receive maintenance niraparib (n = 487) or placebo (n = 246). 1,2 Patients were randomized within 12 weeks of finishing the last cycle of chemotherapy. The study met the primary …

Did you know?

WebApr 12, 2024 · The investigational PARP inhibitor senaparib (JS109/IMP4297) was found to prolong progression-free survival (PFS) in patients with advanced ovarian cancer, meeting the primary end point of the phase 3 FLAMES study (NCT04169997). 1. Senaparib was designed to selectively bind to PARP 1/2 and prevent PARP-mediated repair of single … WebJul 27, 2024 · A Comparison of Platinum-based Therapy With TSR-042 and Niraparib Versus Standard of Care (SOC) Platinum-based Therapy as First-line Treatment of …

WebNiraparib, an inhibitor of poly (adenosine diphosphate [ADP]–ribose) polymerase (PARP), has been associated with significantly increased … WebJul 2, 2024 · Study Description Go to Brief Summary: This study will evaluate the efficacy and safety of niraparib and novel treatment combinations of niraparib as described …

WebNiraparib is marketed in the United States and Europe under the trade name Zejula ®. About PRIMA. PRIMA is a double-blind, randomised Phase 3 study designed to evaluate niraparib versus placebo in first-line Stage III or IV ovarian cancer patients. WebFeb 17, 2024 · Niraparib for maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy Technology …

WebJul 7, 2024 · Despite a very small sample size, it is notable that the median progression-free survival in niraparib plus nivolumab was similar to the placebo group of the POLO study (3·8 months), whereas the median progression-free survival of 10·4 months in the niraparib plus ipilimumab group was closer to that shown in the experimental group of the POLO ...

WebOct 29, 2024 · European Commission approves Zejula (niraparib) as first-line monotherapy maintenance treatment in advanced ovarian cancer . For media and investors only. ... shape of you spaWebOct 29, 2024 · European Commission approves Zejula (niraparib) as first-line monotherapy maintenance treatment in advanced ovarian cancer . For media and investors only. ... The study was later amended to incorporate an individualised starting dose of either 200 mg or 300 mg of Zejula once-daily based on the patient’s baseline … shape of you slowed 1 hourWebNiraparib is a useful option for first-line maintenance therapy for advanced ovarian cancer in adults who responded to platinum-based chemotherapy, regardless of homologous … shape of you slowedWebBackground: This study evaluated maintenance treatment with niraparib, a potent inhibitor of poly(ADP-ribose) polymerase 1/2, in patients with platinum-sensitive recurrent ovarian cancer. Patients and methods: In this phase III, double-blind, placebo-controlled study conducted at 30 centers in China, adults with platinum-sensitive recurrent ovarian cancer … shape of you vietsubWeb1 day ago · In updated findings of the ENGOT-OV16/NOVA trial, final overall survival data of niraparib maintenance therapy showed a benefit for patients with recurrent ovarian cancer; however, mature data showed no significant benefit. ... The phase 2 KGOG3046 is the first study to show survival outcomes with the dual checkpoint blockades, durvalumab and ... shape of you the voicehttp://mdedge.ma1.medscape.com/hematology-oncology/article/209644/gynecologic-cancer/prima-study-niraparib-maintenance-improves-pfs shape of you video lyricsWebMar 23, 2024 · The phase III MAGNITUDE study was designed to compare the efficacy and safety of niraparib + AAP versus placebo + AAP for first-line mCRPC. Clinical data have shown the efficacy of combining androgen receptor–targeted therapy and a PARP inhibitor in metastatic prostate cancer, but the patient population who could have an optimal … shape of you swalla